Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q2 2024 Earnings Conference
Earnings Call Summary | Helius Medical Technologies(HSDT.US) Q2 2024 Earnings Conference
The following is a summary of the Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript:
以下是Helius Medical Technologies公司（HSDT）2024年第二季度業績會簡要概述：
Financial Performance:
金融業績：
Total revenue for Q2 2024 was $182,000, a decrease from $256,000 in Q2 2023.
Operating loss for Q2 2024 remained flat at $3.2 million, the same as the previous year.
Net loss for Q2 2024 was $1.6 million, equivalent to a loss of $0.64 per basic and diluted common share.
2024年第二季度總營業收入爲18.2萬美元，較2023年第二季度的25.6萬美元有所下降。
2024年第二季度運營虧損維持不變，爲320萬美元，與去年相同。
2024年第二季度淨虧損爲160萬美元，基本和攤薄普通股每股虧損0.64美元。
Business Progress:
業務進展：
Helius Medical Technologies has expanded the market for PoNS therapy to the VA and DOD through strategic partnerships, setting a path for broader Medicare and third-party insurer reimbursement.
Significant strides in clinical trials for stroke authorization and securing reimbursement codes and preliminary Medicare payment rates for PoNS devices and mouthpieces.
通過戰略合作，Helius Medical Technologies已將PoNS療法市場擴展到退伍軍人事務部和國防部，爲更廣泛的醫保和第三方保險公司的報銷鋪平了道路。
在腦卒中獲得授權且獲取PoNS設備和口腔裝置初步的醫保支付代碼和預付款率的臨床試驗取得重大進展。
Opportunities:
機會：
Expansion of reimbursed sales channels through partnerships with Lovell Government Services and inclusion in federal supply schedules.
Prospective Medicare reimbursement approval expected to substantially boost revenues post-October 1, 2024.
通過與Lovell Government Services等機構的合作和聯邦供應服務計劃的納入，擴大了報銷銷售渠道。
預計在2024年10月1日後，醫保報銷批准將大大提高營業收入。
Risks:
風險：
Revenue decline due to terminations of temporary programs while transitioning to broader reimbursement pathways might impact short-term financial stability.
由於正在轉向更廣泛的報銷途徑而終止臨時項目可能會影響短期財務穩定，導致營收下降。
More details: Helius Medical Technologies IR
更多詳情：Helius Medical Technologies投資者關係網站
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。